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Abstract
Objective
To compare vitamin D status in women with PCOS versus fertile women and subsequently
evaluate the association between vitamin D status and metabolic disturbances in PCOS
women.
Methods
We conducted a cross-sectional comparison study of 639 women with PCOS and 449 fertile
women. Serum 25-hydroxyvitamin D (25(OH)D) was stratified into a severe deficient (< 25
nmol/l), insufficient (25–50 nmol/l), moderate (50–75 nmol/l) and adequate (> 75 nmol/l) sta-
tus. The main outcome measures were the difference in vitamin D status between PCOS
and fertile women, and the association between serum 25(OH)D and metabolic distur-
bances in PCOS women only.
Results
Serum 25(OH)D was significantly lower in PCOS women compared to fertile controls (mean
25(OH)D of 49.0 nmol/l versus 64.5 nmol/l). An adjusted significant difference was seen
between serum 25(OH)D and homeostasis model assessment (HOMA-IR) (β = 0.76; 95%
CI: 0.63–0.91; p < 0.01), HDL-cholesterol (β = 0.20; 95% CI: 0.05–0.60, p < 0.01) and apoli-
poprotein A1 (β = 26.2; 95% CI: 7.5–45.0, p < 0.01) between the highest vitamin D group
compared to the lowest vitamin D group.
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Conclusions
This study demonstrates that women with PCOS have a significantly lower serum 25(OH)D
compared to fertile controls. A compromised vitamin D status in PCOS women is associated
with a higher HOMA-IR and an unfavourable lipid profile. Large randomized controlled trials
are necessary to explore the causality of this linkage.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of repro-
ductive age, with a prevalence up to 10% depending on which diagnostic criteria are used [1].
It is characterized by ovulatory dysfunction, hyperandrogenism and/or polycystic ovarian
morphology [2]. Metabolic disturbances are present in a majority of the women suffering
from PCOS, i.e. 30–40% have impaired glucose tolerance and insulin resistance with compen-
satory hyperinsulinemia, and as many as 10% will develop type 2 diabetes mellitus during their
fourth decade [3]. Adipose tissue dysfunction has been implicated as a contributor to insulin
resistance in women with PCOS. However, a substantial number of lean women affected by
PCOS have insulin resistance as well, independent of obesity [4,5].
Vitamin D deficiency has been proposed as the possible missing link between insulin resis-
tance and PCOS [6]. Vitamin D is a fat-soluble vitamin that is synthesized endogenously
through sunlight-induced photochemical conversion of cholesterol to 7-dehydrocholesterol in
the skin or obtained from the diet. Subsequently vitamin D undergoes a hydroxylation twice,
first vitamin D is transported to the liver where it is rapidly hydroxylated by 25-hydroxylase
into 25-hydroxyvitamin D (25(OH)D). The second hydroxylation occurs in the kidney and is
catalyzed by 1 alpha-hydroxylase to form 1,25-dihydroxyvitamin D (1,25(OH)2D), the active
metabolite of vitamin D. Circulating 1,25(OH)2D binds to vitamin D receptors (VDR) to initi-
ate its effect. Serum 25(OH)D is the major circulating form of vitamin D and is used as the
main indicator of vitamin D status. Its half-life is 2–3 weeks compared to only 4–6 hours for
1,25(OH)2D [7]. Since many years, a role for vitamin D has been suggested outside the calcium
and bone homeostasis, due to the identification of the VDR, and the enzyme 1 alpha-hydroxy-
lase in many more tissues, including the pancreatic beta-cells, immune cells [8] and reproduc-
tive organs in both genders [6]. Moreover, this assumption is supported by the finding that the
active vitamin D-vitamin D receptor complex regulates over 300 genes, including genes that
are important for glucose and lipid metabolism as well gonadal function [9].
Observational studies have demonstrated a link between vitamin D deficiency and the
onset of and progression of type 2 diabetes [10–13]. Furthermore, low vitamin D status is asso-
ciated with future macrovascular events in patients with type 2 diabetes mellitus [14]. This
association may be the result of the link between vitamin D status and renin-angiotensin sys-
tem [15], endothelial function [16], blood pressure [17] or chronic inflammation [18]. Women
with PCOS seem to have a higher risk for vitamin D deficiency as well [19]. Associations of
vitamin D status and metabolic disturbances have been investigated in a large number of stud-
ies, which are summarized in a systematic review. However, due to the heterogeneity of the
studies, small sample sizes, and small number of studies no firm conclusion could be drawn
[20]. In addition, the association between vitamin D and insulin resistance has been studied
thoroughly in patients with diabetes, resulting in convincing evidence from observational
studies that vitamin D deficiency is inversely related to the degree of insulin resistance [21].
Vitamin D in PCOS
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So far, it is not clear whether vitamin D deficiency is a risk factor for PCOS, and whether
vitamin D status is associated with metabolic disturbances in PCOS women. Therefore, we
performed a cross-sectional comparison study to examine vitamin D status in PCOS women
and fertile women. We also did an analysis in this large PCOS cohort to extend the current
knowledge about the association between vitamin D and metabolic disturbances in PCOS
women.
Materials and methods
Subjects
This retrospective comparison study included 639 PCOS women from the Rotterdam PCOS
cohort and 449 fertile women from the HAVEN cohort, which are further mentioned through-
out the manuscript as control women. PCOS women who were screened for anovulatory infer-
tility at the outpatient clinic of the Erasmus Medical Center Rotterdam, and subsequently
diagnosed with PCOS according to the Rotterdam criteria were eligible for inclusion in this
study. Trained professionals performed the screening procedure according to a standardized
protocol which has been previously described in greater detail [22]. First, a thorough general
medical, reproductive and family history was taken, including self-reported ethnicity. Second,
anthropometric measurements were performed, including height, weight, body mass index
(BMI), waist circumference measured midway between the arcus costae and anterior superior
iliac spine, hip circumference measured at the level of the anterior superior iliac spine, systolic
and diastolic blood pressure, and the level of hirsutism measured with the use of the Ferriman-
Gallwey (FG) score. Subsequently, a systematic transvaginal ultrasonography was performed
to assess ovarian volume, endometrial thickness, and the total number of antral follicles mea-
suring 2–10 mm. Finally, an extensive metabolic and endocrine profile was assessed.
PCOS was diagnosed according to the Rotterdam criteria; i.e., requiring the presence of at
least two out of the three following criteria: ovulatory dysfunction resulting in oligomenorrhea
(mean bleeding interval 35–182 days in last six menstrual bleeds) and/or amenorrhea (absence
of menstrual bleeding for>182 days), hyperandrogenism and/or hirsutism, and the presence
of polycystic ovarian morphology (PCOM) [23]. Clinical and biochemical hyperandrogenism
was defined as an FG score >8, and/or a free androgen index (FAI: [(T/SHBG) x 100]>4.5)
[24]. Women were excluded if the blood draw was not performed in a fasting state.
Control women were recruited at child health centers in the same geographic area as the
study population. This group consisted of a random group of mothers who had a spontaneous
and uneventful pregnancy and delivered a healthy child without congenital malformations.
They were all assessed, at 15–17 months after delivery at the hospital using a standardized
study protocol. These women have been described previously [24,25]. Information on general
health and cycle history was gathered by questionnaire. This study was approved by the Cen-
tral Committee on Research Involving Human Subjects (the Hague, The Netherlands) and the
institutional review board at the Erasmus Medical Center. Informed consent was obtained
from all participants.
Assessment of metabolic profile and vitamin D. Regarding the cardiovascular profile,
information was collected on BMI and systolic and diastolic blood pressure in both PCOS and
comparison women. In PCOS women, waist circumference, fasting glucose, insulin and lipid
profile (i.e. total cholesterol, triglycerides, high-density lipoprotein cholesterol and low-density
lipoprotein cholesterol) were additionally measured. Insulin resistance was assessed using the
homeostasis model assessment (HOMA-IR: [fasting glucose (mmol/L) x fasting insulin [mU/
L]]/22.5). Metabolic syndrome was defined according the National Cholesterol Education Pro-
gram (NCEP) ADP III criteria [26].
Vitamin D in PCOS
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Venous blood samples were drawn at examination and stored at −80˚C after centrifugation
at 3000 rpm for 10 min at 20˚C. Serum 25(OH)D was measured using the liquid chromatogra-
phy tandem-mass spectrometry (LC-MS/MS) in November 2013 (PCOS women) and Septem-
ber 2015 (control women). Liquid-liquid extraction (hexane) of the samples and analysis,
carried out with a Waters ACQUITY UPLC system couple to a Waters Xevo TQ mass spec-
trometer, were performed as described elsewhere [27]. Intra-assay coefficients of variation
(CV) was < 6% and intra-assay CV was < 9% at the concentration of 16 and 80 nmol/L,
respectively. The measurement of serum 25(OH)D was carried out by the central chemical lab-
oratory of the Medical Center Alkmaar, the Netherlands. This laboratory is a (ISO-15189) cer-
tified laboratory.
Endocrine evaluation included serum levels of gonadotropic hormones (LH, FSH) and
estradiol (E2), testosterone, dehydroepiandrosterone sulfate (DHEAS), fasting glucose and
insulin. Hormone assays have been described in detail elsewhere [28]. Insulin was measured
by immunoradiometric assay. Testosterone, E2 and DHEAS were determined by radioimmu-
nometric assays (RIAs). Intra-assay and inter-assay CV were less than 3% and less than 5% for
testosterone and less than 5% and less than 7% for E2 respectively.
Statistical analyses
Data are presented as means ± standard deviation if normally distributed, and as median and
interquartile range in case of a skewed distribution. For the main analyses we compared PCOS
women with fertile controls regarding vitamin D status. We used a linear regression analysis
with serum 25(OH)D as dependent variable and PCOS versus control as independent variable.
We adjusted for BMI, age, blood pressure, season of vitamin D measurement, and ethnicity as
potential confounders or effect modifiers. Serum 25(OH)D was log transformed due to a non-
gaussian distribution. The exponentiated beta-coefficients are reported as results of the regres-
sion analyses.
Sub-analyses were performed to assess the association between vitamin D status and meta-
bolic outcome parameters in women with PCOS, by applying multivariable linear regression
analyses. As the relationship between serum 25(OH)D and the outcome measures was not lin-
ear, serum 25(OH)D was divided in four groups by the widely used cut-off values of vitamin
D: 1) serum 25(OH)D: < 25 nmol/l, 2) serum 25(OH)D: 25–50 nmol/l, 3) serum 25(OH)D:
51–75 nmol/l, and 4) serum 25(OH)D: > 75 nmol/l [20]. The vitamin D group with a serum
25(OH)D > 75 nmol/l was used as reference value. Regarding the lipid profile the highest vita-
min D group (> 75 nmol/l) was compared to the lowest vitamin D group (< 25 nmol/l). We
adjusted for confounding variables which are known to influence the association between vita-
min D level and cardiovascular outcomes (e.g. BMI, lipid profile, ethnicity etc.). A p-
value < 0.05 was considered statistically significant. All data were analysed using the Statistical
Package of the Social Sciences (SPSS software, version 22.0; SPSS Inc., Chicago, IL).
Results
Vitamin D status in PCOS and control women
A total of 639 PCOS women and 449 fertile control women were included in the analyses.
Demographic, anthropometric and clinical characteristics are presented in Table 1. The mean
age was 34 ± 5 and 32 ± 5 years, with a median BMI of 25.2 (22.0–30.4 kg/m2) and 24.0 (22.0–
27.0 kg/m2) in PCOS and control women, respectively. Overall median serum 25(OH)D was
49.0 (27.1–74.1 nmol/l) in PCOS versus 64.5 (39.2–85.7) in the control women. A severe vita-
min D deficiency was present in 136 (21%) women out of 639 PCOS women, 190 (30%)
women had a serum 25(OH)D between 25.1 and 50.0 nmol/l, 165 (26%) women had a serum
Vitamin D in PCOS
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25(OH)D between 50.1 and 75.0 nmol/l, and 148 (23%) women had a serum 25(OH)D > 75
nmol/l. In the control group 49 (11%) women had a serum 25(OH)D� 25 nmol/l, 106 (24%)
women between 25.1 and 50.0 nmol/l, 131 (29%) women between 50.1 and 75.0 nmol/l, and
163 (36%) women had a serum 25(OH)D > 75 nmol/l. Linear regression analysis showed a
lower serum 25(OH)D for the PCOS women compared to control women (β = 0.78; 95% CI:
0.72–0.84, p < 0.01) (Table 2). Correcting this analysis for age, BMI, blood pressure, ethnicity
and season the difference remained significant (β = 0.93; 95% CI: 0.87–0.99, p = 0.03).
PCOS women
Demographic, anthropometric and clinical characteristics of all PCOS women, stratified by
vitamin D group are presented in Table 3. The majority (60%) of included women were of
Caucasian ethnicity. The distribution of the various ethnicities differed significantly between
women with a severe vitamin D deficiency compared to women with a sufficient vitamin D
status, with 92% Caucasian women in the highest vitamin D group versus 14% of the women
in the lowest vitamin D group. An expected difference was seen in season of measurement
between the vitamin D groups, with the highest percentage of blood samples taken in the sum-
mer presenting in the highest vitamin D group and the lowest percentage of blood samples
taken in the summer in the lowest vitamin D group (48% versus 19%, respectively).
Table 2. Linear regression analysis of serum 25(OH)D� in PCOS versus fertile controls.
B (95% CI) p
Model 1: crude analysis 0.78 (0.72–0.84) < 0.01
Model 2: Model 1 + age, BMI and systolic blood pressure 0.79 (0.73–0.86) < 0.01
Model 3: Model 2 + season and ethnicity 0.93 (0.87–0.99) 0.03
� serum 25(OH)D was natural log transformed
25(OH)D, 25-hydroxy vitamin D; BMI, body mass index
https://doi.org/10.1371/journal.pone.0204748.t002
Table 1. Baseline characteristics of PCOS and fertile control women.
PCOS Control p-value
N 639 449
Age (y) 34 ± 5 32 ± 5 < 0.01
Body Mass Index (kg/m2) 25.2 (22.0–30.4) 24.0 (22.0–27.0) < 0.01
Ethnicity (%)
Caucasian 385 (60) 382 (85) < 0.01
Non-Caucasian 254 (40) 67 (15)
Season of blood collection
Winter 145 (23) 114 (25) 0.30
Spring 114 (18) 142 (32) < 0.01
Summer 207 (32) 93 (21) < 0.01
Autumn 173 (27) 200 (22) 0.07
BP systolic (mmHg) 118 ± 13 114 ± 11 < 0.01
BP diastolic (mmHg) 77 ± 11 73 ± 9 < 0.01
Serum 25(OH)D (nmol/l) 49.0 (27.1–74.1) 64.5 (39.2–85.7) < 0.01
Storage of samples (years) 6 10 < 0.01
25(OH)D, 25-hydroxy vitamin D; BP, blood pressure.
https://doi.org/10.1371/journal.pone.0204748.t001
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Anthropometric parameters
Median BMI of all PCOS women included was 25.2 (22.0–30.4 kg/m2). Overweight/obese
women (BMI> 25 kg/m2) had a mean serum 25(OH)D 46.3 ± 27.9 nmol/l, which was signifi-
cantly lower compared to women with a BMI < 25: serum 25(OH)D 59.7 ± 30.0 nmol/l
(p< 0.01). A total of 94 (15%) women fulfilled the NCEP APT III criteria for metabolic syn-
drome, who had a significant lower serum 25(OH)D than women without metabolic syn-
drome (mean serum 25(OH)D 44.3 ± 27.4 nmol/l and 54.2 ± 29.9 nmol/l (p< 0.01),
respectively).
Table 3. Baseline demographic and clinical characteristics.
Vitamin D groups (serum 25(OH)D)
All < 25.0 nmol/l 25.0–50.0 nmol/l 50.1–75.0 nmol/l > 75.0 nmol/l
N 639 136 190 165 148
Age (y) 34 ± 5 32 ± 5 33 ± 6 34 ± 6 35 ± 5
Ethnicity (%)
Caucasian 385 (60) 19 (14) 101 (53) 129 (78) 136 (92)
Non-Caucasian 254 (40) 117 (86) 89 (47) 36 (22) 12 (8)
Season of blood collection
Winter 145 (23) 40 (29) 52 (27) 33 (20) 20 (14)
Spring 114 (18) 31 (23) 35 (19) 31 (19) 17 (11)
Summer 207 (32) 25 (19) 52 (27) 59 (36) 71 (48)
Autumn 173 (27) 40 (29) 51 (27) 42 (25) 40 (27)
Storage (y) 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1
Body Mass Index (kg/m2) 26.6 ± 6.0 29.1 ± 6 26.7 ± 6.1 26.4 ± 5.9 24.3 ± 5.3
Waist/hip ratio 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
FG score 5 (1–8) 9 (2–13) 5 (1–7) 4 (0–5) 4 (0–6)
BP systolic (mmHg) 118 ± 13 119 ± 12 118 ± 13 118 ± 13 117 ± 13
BP diastolic (mmHg) 77 ± 11 78 ± 11 77 ± 10 77 ± 11 76 ± 9
Metabolic syndrome yes (%) 90 (15) 33 (24) 26 (14) 23 (14) 12 (8)
Serum 25(OH)D (nmol/l) 49.0 (27.1–74.1) 16.8 (12.9–21.4) 37.0 (30.0–43.4) 62.9 (56.3–69.9) 94.2 (81.7–102.4)
Fasting glucose (mmol/L) 4.33 ± 0.68 4.49 ± 0.73 4.37 ± 0.78 4.28 ± 0.57 4.20 ± 0.55
Fasting insulin (mU/L) 10.0 (4.6–12.4) 14.2 (6.2–18.2) 10.6 (5.3–12.8) 8.5 (4.6–10.9) 7.2 (3.5–9.4)
HOMA-IR 1.99 (0.85–2.46) 2.94 (1.13–3.66) 2.09 (0.95–2.48) 1.64 (0.85–2.13) 1.36 (0.66–1.72)
Total cholesterol (mmol/L) 5.1 ± 1.2 5.0 ± 1.3 5.1 ± 1.2 5.2 ± 1.3 5.2 ± 1.1
LDL-cholesterol (mmol/L) 3.6 ± 1.0 3.6 ± 1.0 3.6 ± 1.0 3.7 ± 1.1 3.7± 1.0
HDL-cholesterol (mmol/L) 1.4 ± 0.5 1.3 ± 0.4 1.4 ± 0.5 1.5 ± 0.5 1.6 ± 0.5
Triglycerides (mmol/L) 1.1± 0.7 1.2 ± 0.8 1.1 ± 0.6 1.2 ± 0.7 0.9 ± 0.4
TC/HDL ratio (mmol/L) 3.9 ± 1.4 4.3 ± 1.6 3.9 ± 1.3 3.8 ± 1.4 3.5 ± 1.3
Apo A1 (g/L) 213.3 ± 59.4 198.1 ± 47.6 215.4 ± 59.2 215.6 ± 67.8 221.9 ± 57.3
Apo B (g/L) 121.9 ± 37.9 126.5 ± 42.1 123.1 ± 37.0 120.8 ± 37.8 117.1 ± 34.6
Testosterone (nmol/L) 2.01 (1.40–2.50) 2.18 (1.50–2.70) 2.02 (1.30–2.60) 1.96 (1.40–2.40) 1.89 (1.20–2.35)
Free androgen index 6.5 (3.0–8.6) 9.3 (4.9–12.6) 6.7 (3.1–8.9) 5.6 (2.8–7.5) 4.6 (2.1–6.3)
Estradiol (pmol/L) 301 (176–361) 285 (181–361) 301 (179–356) 313 (175–361) 302 (168–394)
DHEAS (μmol/L) 5.36 ± 2.47 5.51 ± 2.89 5.36 ± 2.34 5.18 ± 2.35 5.42 ± 2.37
AMH (μg/L) 11.0 (6.0–14.2) 10.2 (5.8–12.7) 10.1 (5.6–13.6) 11.0 (6.0–14.9) 12.7 (6.8–15.1)
25(OH) D, 25-hydroxy vitamin D; AMH, antiMullerian hormone, APO, apolipoprotein; BP, blood pressure; DHEAS, dehydroepiandrosteron sulfate; FG, Ferriman–
Gallwey; FSH, follicle stimulating hormone, HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment–insulin resistance; LDL, low density lipoprotein;
LH, luteinizing hormone, TC, total cholesterol; TG, triglycerides; TSH, thyroid stimulating hormone
https://doi.org/10.1371/journal.pone.0204748.t003
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Glycemic parameters
Linear regression analysis correcting for BMI, ethnicity, waist to hip ratio, cholesterol/HDL
ratio, and season resulted in a significant difference in HOMA-IR between the highest and
lowest vitamin D groups. In the women with the lowest vitamin D level, HOMA-IR was on
average 24% higher compared to the women with the highest vitamin D level (β = 0.76; 95%
CI: 0.63–0.91; p< 0.01, Table 4) (Fig 1). Also, a significant difference was found between the
middle vitamin D group with a serum 25(OH)D between 25.1 and 50.0 nmol/l and the highest
vitamin D group (β = 0.83; 95% CI: 0.72–0.96, p = 0.01). No significant difference was found
between the middle-high vitamin D group (serum 25(OH)D: 50.1–75.0 nmol/l) compared to
the women with a serum 25(OH)D > 75 nmol/l regarding HOMA-IR. No significant differ-
ence between the vitamin D groups was seen in fasting glucose after correction for BMI, age,
ethnicity and season (β = -0.18; 95% CI: -0.39–0.03, p = 0.09).
Lipid profile
Mean total cholesterol (TC) /HDL ratio was 3.9 ± 1.4 mmol/L in our study population. The
ratio differed significantly between the vitamin D groups with a difference of -0.79 mmol/L
between the lowest and highest vitamin D group (p< 0.01). After correcting for confounders,
the association did not remain significant between the lowest and highest vitamin D groups
(B = -0.31; 95% CI: -0.73–0.12, p = 0.16). A significant difference was seen in HDL-cholesterol
between the lowest and highest vitamin D group after correction for confounders (B = 0.20;
Table 4. Linear regression analysis of vitamin D groups� and HOMA-IR��.
Exp(B) (95% CI) p-value
Model 1: crude analysis
1.Serum 25(OH)D� 25.0 nmol/l 0.49 (0.41–0.58) < 0.01
2.Serum 25(OH)D 25.1–50.0 nmol/l 0.68 (0.57–0.80) < 0.01
3.Serum 25(OH)D 50.1–75.0 nmol/l 0.80 (0.67–0.94) < 0.01
Model 2: Model 1 + BMI
1.Serum 25(OH)D� 25.0 nmol/l 0.70 (0.60–0.81) < 0.01
2.Serum 25(OH)D 25.1–50.0 nmol/l 0.81 (0.71–0.93) < 0.01
3.Serum 25(OH)D 50.1–75.0 nmol/l 0.90 (0.79–1.04) 0.15
Model 3: Model 2 + ethnicity
1.Serum 25(OH)D� 25.0 nmol/l 0.75 (0.62–0.89) < 0.01
2.Serum 25(OH)D 25.1–50.0 nmol/l 0.84 (0.73–0.97) 0.02
3.Serum 25(OH)D 50.1–75.0 nmol/l 0.91 (0.79–1.05) 0.20
Model 4: Model 3 + W/H ratio, Chol/HDL ratio
1.Serum 25(OH)D� 25.0 nmol/l 0.76 (0.65–0.91) < 0.01
2.Serum 25(OH)D 25.1–50.0 nmol/l 0.84 (0.73–0.96) 0.01
3.Serum 25(OH)D 50.1–75.0 nmol/ 0.91 (0.80–1.04) 0.19
Model 5: Model 4 + season
1.Serum 25(OH)D� 25.0 nmol/l 0.76 (0.63–0.91) < 0.01
2.Serum 25(OH)D 25.1–50.0 nmol/l 0.83 (0.72–0.96) 0.01
3.Serum 25(OH)D 50.1–75.0 nmol/l 0.91 (0.79–1.04) 0.16
BMI, body mass index; Chol/HDL ratio, cholesterol–high-density lipoprotein ratio; W/H ratio, waist to hip ratio
� Vitamin D group with serum 25(OH)D > 75 nmol/l is the reference group
��HOMA-IR natural logarithm (0.76 means 1–0.76 = 24% higher HOMA-IR in vitamin D group� 25 nmol/l
than > 75 nmol/l)
https://doi.org/10.1371/journal.pone.0204748.t004
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95% CI: 0.05–0.60, p< 0.01). Apolipoprotein A1 was significantly higher in the highest vita-
min D group compared to the lowest group after correction for confounders (B = 26.2; 95%
CI: 7.5–45.0, p< 0.01). A small significant difference was seen in serum total cholesterol dem-
onstrating higher serum total cholesterol in the highest vitamin D group compared to the low-
est vitamin D group (B = 0.41; 95% CI: 0.02–0.70, p = 0.05). No difference between the vitamin
D groups was found in serum triglycerides, LDL-cholesterol, and apolipoprotein B (Table 5).
Conclusions
The aim of this study was 1) to explore vitamin D status in women with PCOS compared to
fertile controls and 2) to evaluate the associations between vitamin D status and metabolic dis-
turbances in PCOS women. In this study the lower vitamin D status in women with PCOS
compared to fertile controls was confirmed [20]. Low serum 25(OH)D status is significantly
associated with a higher insulin resistance in women with PCOS independent of major
Fig 1. Association between serum 25(OH)D (nmol/l) groups and HOMA-IR and BMI.
https://doi.org/10.1371/journal.pone.0204748.g001
Table 5. Regression analysis of serum 25(OH)D> 75 nmol/l versus< 25 nmol/l and parameters of lipid profile.
Model I Model II Model III
B (95% CI) p B (95% CI) p B (95% CI) p
TC (mmol/L) 0.16 (-0.13–0.46) 0.27 0.34 (0.04–0.65) 0.03 0.41 (0.02–0.70) 0.05
TG (mmol/L) -0.28 (-0.44 –-0.12) < 0.01 -0.12 (-0.28–0.04) 0.13 -0.14 (-0.35–0.06) 0.18
HDL (mmol/L) 0.34 (0.23–0.45) < 0.01 0.23 (0.12–0.34) < 0.01 0.20 (0.05–0.34) < 0.01
LDL (mmol/L) 0.05 (-0.20–0.29) 0.70 0.24 (0.00–0.49) 0.06 0.28 (-0.04–0.60) 0.09
TC/HDL ratio (mmol/L) -0.79 (-1.12 –-0.46) < 0.01 -0.33 (-0.65 –-0.01) 0.048 -0.31 (-0.73–0.12) 0.16
Apo A1 (g/L) 23.1 (9.2–37.0) < 0.01 18.6 (4.1–33.1) 0.01 26.2 (7.5–45.0) < 0.01
Apo B (g/L) -9.8 (-18.9 –-0.8) 0.03 -0.03 (-9.1–9.0) 0.99 7.9 (-3.6–19.5) 0.18
Model 1: crude.
Model 2: adjusted for BMI, fasting glucose
Model 3: adjusted for BMI, fasting glucose, season, ethnicity and age
25(OH) D, 25-hydroxy vitamin D; Apo, apolipoprotein; HDL, high density lipoprotein; LDL, low density lipoprotein; TC, total cholesterol; TG, triglycerides
https://doi.org/10.1371/journal.pone.0204748.t005
Vitamin D in PCOS
PLOS ONE | https://doi.org/10.1371/journal.pone.0204748 December 4, 2018 8 / 13
confounders as BMI, season and ethnicity. Moreover, women with PCOS and a severe vitamin
D deficiency had the lowest levels of HDL cholesterol and apolipoprotein A1.
The strength of our study is that we have studied the largest cohort of PCOS women and
compared our findings with a comparison group without PCOS, which allows a well-powered
comparison. Second, all samples were measured using the LC-MS/MS method, which is the
golden standard for measurement of serum 25(OH)D [27].
A disadvantage of our study is that metabolic measurements were not available in the fertile
control women. Although the control women were enrolled from the general population and
not selected on fertility, it is not likely that a substantial part of the control women had PCOS
due to the fact that they all had a spontaneous pregnancy and regular menstrual cycles before
pregnancy. The blood collection of the control women was carried out 15 to 17 months after
delivery to exclude the effect of pregnancy on vitamin D metabolism. Another limitation of
our study could be that the comparison group was not originally created as a control group for
this study and was matched retrospectively, resulting in a small difference in age and BMI
between both groups. Taken this into account we labelled the study not as a case-control
study, but as a comparison study. However, this was the best control group available in the
same region and age category, of which we were certain all women had a spontaneous preg-
nancy which makes the chance of PCOS and thus confounding in this group very low.
Although serum 25(OH)D is stable over time, theoretically long-time storage of serum sam-
ples at -80 ˚C could have influenced the vitamin D concentration [29]. However, any influence
of the storage time on vitamin D level does not seem very likely as the mean storage time in
control women, which demonstrated to have a higher mean serum 25(OH)D concentration,
was significantly higher than in PCOS women (10 versus 6 years).
Another important point is the possibility of residual confounding which cannot be ruled
out, despite correction for several confounders. Last limitation could be that we have used a
surrogate marker of insulin resistance (HOMA-IR) and not the golden standard to measure
insulin resistance, i.e. insulin clamp technique.
Interpretation of study findings
Several epidemiologic studies have explored the effect between vitamin D status and metabolic
disturbances in PCOS women and controls. These studies are summarized in an earlier sys-
tematic review [20], in which was concluded that serum 25(OH)D is a significant predictor for
insulin resistance in PCOS women. However, this effect disappeared after adjustment for BMI.
Important limitations of the earlier performed observational studies were the small sample
sizes and poor analyses with lack of correcting for confounding factors as ethnicity, season of
blood collection and BMI.
The finding of a higher prevalence of vitamin D defiency in PCOS women compared to
(fertile) controls is in line with earlier reports, which observed a percentage of vitamin D defi-
ciency (defined as serum 25(OH)D < 50nmol/l) of 67–85% among women with PCOS [19].
The mean vitamin D level in control women of our study was comparable with the overall
mean vitamin D level that was reported in control women in the earlier performed systematic
review [20]. However, the mean vitamin D level in women with PCOS appeared to be much
lower than reported in the same review. This discrepancy could be explained by the finding of
a discrepant higher vitamin D level in PCOS women compared to controls in some of the
reviewed studies, which could be caused by the lack of adjustment for major confounders (i.e.
the season of measurement of vitamin D level and ethnicity) [30–32]. Moreover, PCOS
women with hirsutism could have less sun exposure and consequently a lower vitamin D
synthesis.
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To date, there is still a debate what the optimal serum 25(OH)D level is. The Institute of
Medicine [33] has determined that serum 25(OH)D levels greater than 50 nmol/l are sufficient
based on the current studies available, although other experts advise that optimal levels should
be higher (> 75 nmol/l) [34]. In our study population only 138/639 (22%) had a serum 25
(OH)D concentration > 75 nmol/l. In the groups with lower serum 25(OH)D a more dis-
turbed metabolic profile was seen; higher levels of insulin resistance and a worse lipid profile,
supporting the recommendation from the Endocrine Society to reach a serum 25(OH)D
concentration > 75 nmol/l.
Vitamin D is thought to influence the development of PCOS through gene transcription
and influences metabolism [35]. The effect of vitamin D status on glucose metabolism appears
to be mediated by direct and indirect pathways. A direct effect on insulin secretion may be
mediated by activation of VDRs in the pancreatic beta-cell with the addition of the presence of
1α-hydroxylase to locally produce 1,25(OH)2D. Furthermore, the direct effect of vitamin D on
insulin secretion is supported by the presence of the vitamin D-response element in the
human insulin promoter gene [36]. Vitamin D deficiency may also increase systemic inflam-
mation, known to play an important role in the pathogenesis of insulin resistance [18]. Finally,
insulin secretion and insulin resistance are both calcium-dependent processes. Both could be
influenced by vitamin D status through an alteration in calcium concentration and flux
through cell membranes of pancreas and insulin-responsive tissues.
Next to the linkage of vitamin D to the pathogenesis of PCOS, vitamin D may also effect fer-
tility outcomes in PCOS [37]. Vitamin D supplementation may improve ovulatory dysfunction
and thereby fertility in PCOS women [38, 39]. This may be explained by the finding that VDR
has been found across several tissues within the female reproductive system (i.e. ovarian,
decidua, placenta and endometrium cells) [40–41]. Furthermore, 1,25(OH)D2 directly leads to
the production of estrogen and progesterone in cultured human ovary and placental cells
[42,43]. Moreover, an inverse association between vitamin D concentration and anti-Mu¨lle-
rian hormone (AMH) has been reported. Elevated AMH reflects abnormal folliculogenesis in
PCOS women [44,45]. In the literature women more often have lower vitamin D levels com-
pared to men [46]. An underlying association between vitamin D levels with androgens as an
explanation could, however, not be found[38].
The association found between vitamin D and dyslipidemia (i.e. HDL-cholesterol and apo-
lipoprotein A1) had previously been described [47]. Low HDL-cholesterol is one of the central
features of metabolic syndrome. As dyslipidemia should be considered as an additional thera-
peutic target in women suffering from PCOS [48], vitamin D might be useful in the complex
treatment of these women.
Apart from these cross-sectional findings, several intervention trials examined the effects of
vitamin D supplementation on metabolic parameters and clinical parameters including fertil-
ity in PCOS women. These studies differed in study design, population, dosing regimens, as
well as study outcomes [40,49]. A significant inverse association was found between serum 25
(OH)D and insulin resistance in the included observational studies, which is in line with our
results. Some RCTs had promising results regarding vitamin D effects on metabolic as well as
on fertility aspects. However, overall no significant improvement in metabolic functions and
fertility outcome was found among PCOS women supplemented with vitamin D.
This could be due to the inconsistencies in study design, included PCOS populations and
duration of follow up. The largest study with a RCT design among 104 obese, vitamin D defi-
cient PCOS women did reveal a positive effect of weekly 50.000 IU vitamin D plus calcium
1000mg/day on insulin resistance [50].
In conclusion, this is the largest epidemiologic study showing a significant association
between vitamin D status and metabolic disturbances in patients with PCOS. Moreover, PCOS
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women had a significant lower serum 25(OH)D compared to fertile controls. For future
research large randomized controlled clinical trials are necessary to explore whether this asso-
ciation has a causal linkage.
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